anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Highly purified, biologically active Human Antihemophilic Factor (AHF) preparations are prepared having specific activities of about 4000 - 8000 units per milligram of AHF. In the method of preparation an AHF concentrate, prepared by fractionation of plasma to partially remove fibrinogen, fibronectin and other plasma components is subjected to a separation on the basis of Stokes' radius to separate AHF from the bulk of remaining proteins in the AHF concentrate. The pooled fractions containing AHF activity are concentrated by precipitation with ammonium sulfate, sodium sulfate, etc., by diafiltration, by PEG addition, or the like. The concentrate, is solubilized or equilibrated in an aqueous medium and treated to change the effective Stokes' radius of the AHF to an apparently low value and then subjected to a separation from the concentrate. The AHF pool from above is treated to remove cations by dialysis against an appropriate buffer of lower ionic strength and chromatographed on an anion-exchange medium. The AHF fraction from the above chromatography, is a highly purified AHF preparation.
A composition which is at least substantially anhydrous and comprises a. At least one water immiscible emollient oil in sufficient quantity to provide emollience to skin, b. At least one emulsifying agent capable of forming an emulsion, in situ, on the skin with the above oil when water is added to the said composition, the said emulsifier in such quantities that the oil is substantially removed from the skin, c. A physical stabilization of the composition enhancing amount of a component selected from the group consisting of 1). At least one wax, 2). At least one oil gelling agent that is both water and oil insoluble, and 3). A mixture of 1 and 2.
The present invention relates to a preparation method of an antifungal freeze dried powder injection and a transfusion which contain itraconazole. The present invention belongs to a preparation method of an antifungal medicament preparation. Before the freeze dried powder injection and the transfusion are prepared, itraconazole compositions need to be prepared, and the technologies are the same. In the step for preparing the itraconazole composition, the weight ratio of itraconazole to cyclodextrin to acid is equal to 1:2 to 22:0.1 to 2.0, the itraconazole, the cyclodextrin and the acid are dissolved with distillation water, methanol, etc., obtained solution is heated, stirred, frozen, dried and filtered, transparent liquid is obtained, and the itraconazole composition is prepared. In the step for preparing the freeze dried powder injection, the weight ratio of the itraconazole composition to the cyclodextrin is equal to 1:0.5 to 10, the itraconazole composition and the cyclodextrin are dissolved with distillation water, the pH value of solution is regulated to be equal to 4 to 9 with NaOH, pyrogen is eliminated by activated carbon, the solution is filtered, frozen and dried, and the freeze dried powder injection which contains itraconazole is obtained. The performance of the freeze dried powder injection is stable, and the storage and the transportation are convenient. The transfusion can effectively avoid infection caused by the operation that powder and injection solution are put into salt solution because transfusion is prepared.
Unplanned pregnancies and sexually transmitted infections are important and costly public health problems in the United States resulting from unprotected sexual activity. Women with a history of incarceration are at increased risk for these problems given the high rates of substance abuse and commercial sex work in this population. This proposal is designed to evaluate an innovative intervention Motivational Interviewing with Computer Assistance (MICA) designed to improve contraceptive use for incarcerated women who do not want a pregnancy and are soon to be released into the community. The investigators will utilize the Title X program which, in conjunction with RI Department of Corrections (RI DOC), provides reproductive health services in jail and then transitional services in the community after release. The investigators plan to recruit 400 women from the RI DOC women's jail and randomize them to two interventions: two sessions of personalized MICA or two sessions of Didactic Educational Counseling (DEC), both delivered individually by trained counselors. The two counseling interventions will be similar in length and timing, but will vary in content, counseling style and the individualized computer generated feedback that is reviewed with the counselor.
Deficiency of X-linked inhibitor of apoptosis protein (XIAP) is a rare genetic condition that can present with recurrent episodes of hemophagocytic lymphohistiocytosis (HLH), though the exact mechanisms leading to this hyperinflammatory disorder are unclear. Understanding its biology is critical to developing targeted therapies for this potentially fatal disease. Here, we report on a novel multiexonic intragenic duplication leading to XIAP deficiency with recurrent HLH that demonstrated complete response to interleukin (IL)-1β blockade. We further demonstrate using both primary patient cells and genetically modified THP-1 monocyte cell lines that, contrary to what has previously been shown in mouse cells, XIAP-deficient human macrophages do not produce excess IL-1β when stimulated under standard conditions. Instead, nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated hyperproduction of IL-1β is observed only when the XIAP-deficient cells are stimulated under autophagy-promoting conditions and this correlates with defective autophagic flux as measured by decreased accumulation of the early autophagy marker LC3-II. This work, therefore, highlights IL-1β blockade as a therapeutic option for patients with XIAP deficiency experiencing recurrent HLH and identifies a critical role for XIAP in promoting autophagy as a means of limiting IL-1β-mediated hyperinflammation during periods of cellular stress.
BACKGROUND: Comprehensive, patient-specific models are essential to study calcium deposition and mobilization during dialysis. We aim to develop tools to support clinical prescriptions with a more accurate approach for the prediction of calcium mobilization while also considering major electrolytes and catabolites.
METHODS: We modified a multi-solute model predicting patient-specific dialysis response by incorporating a calcium buffer to represent bone exchanges. Data from four centers, involving 127 patients with six sessions each, were utilized. For each patient, three sessions were allocated for model training (ID123), while the remaining sessions were for validation (PRED456). The normalized root mean square error (nRMSE%) was used to evaluate both descriptive and predictive accuracy. Correlations between initial data and calcium exchanges were also assessed.
RESULTS: The overall nRMSE% for ID123 was 3.92%. For PRED456, it was 3.46% (ranging from a minimum of 1.17% for [Na+] to a maximum of 6.62% for [urea]). The median nRMSE% for plasma calcium varied between 1.13 and 8.32 for SHD sessions, depending on whether Ca_dialysis fluid (Cad) was ≥ or <1.50 mmol/L, respectively. For HDF sessions, the range was between 2.90 and 5.89. A significant and moderate correlation was found between overall calcium removal and the buffer balance. The most robust correlation observed was between the amount of calcium administered via post-dilution fluid and the overall calcium removal in the dialysis filter.
CONCLUSIONS: Identical therapy settings do not uniformly affect calcium mobilization, and our approach offers insight into calcium distribution across body compartments. This understanding will enhance clinical prescription practices.
Participants will receive a selected dose of BT7480 and standard dose of nivolumab. It is expected that approximately 45 patients will participate in this dose expansion arm in Phase 2.
The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).
Swallowing problems (dysphagia) are encountered frequently in primary practice and in the hospital setting. The list of possible causes is large, ranging from strokes and neurological disease to complications of cancer treatment, acid reflux, and surgery. Many patients have a reduced ability to feel food and fluid (reduced sensation) within the throat (pharynx) and this leads to an inability to manipulate food and fluids in the correct manner. This can produce a variety of swallowing problems such as choking on foods and fluids, regurgitation, aspiration, weight loss, malnutrition and poor quality of life.

Treatment of dysphagia is largely directed at rehabilitation of muscle power and education about safe swallowing techniques or positioning that limits food and fluid from entering the airway. One of the most widely accepted treatments of dysphagia is to alter the texture of food. Most patients with dysphagia will have more difficulty swallowing thin liquids. By adding a thickener to the liquid, a food bolus becomes more cohesive, and is less likely to become aspirated. Various types of thickening products are available over-the-counter without a prescription. These thickening products are bland and currently have no flavor. We hypothesize that alterations in food taste (sweet, salty, etc...), viscosity, and temperature, will improve swallowing efficiency. The purpose of this investigation is to evaluate the effects of food taste, texture, and temperature on swallowing efficiency. The goal is to develop safer, better tasting food products and improve the quality of life in patients with disabling swallowing disorders.
Vaccines have had monumental impact in reducing the mortality and morbidity of infectious disease. However, the underlying immune mechanisms that contribute to their effectiveness are incompletely understood. Transcriptomics (methods that measure the activity of thousands of genes) studies have identified key features of responses to vaccination(see references) and infection(see references). However, these experiments are typically performed on heterogeneous cell mixtures such as peripheral blood mononuclear cells (PBMC which include certain types of white blood cells) and therefore provide an aggregate measure of gene expression from the many different immune cells and their respective activities in the mixture. Such results can obscure important biological information, particularly in minor subsets of active cells. Establishing a method for immune transcriptomics at single cell resolution would be a highly significant advance and enable more informative and functionally relevant systems immunology studies with commonly used sample types (i.e. PBMC). Applying this high-resolution approach to Yellow Fever Vaccine (YFV), an exceptionally effective vaccine, is likely to identify unappreciated mechanisms that contribute to protective immunity.
The purpose of the proposed study is to preliminarily evaluate a technology-based program in improving health outcomes of Asian American midlife women who are family caregivers of persons living with Alzheimer's disease (AACA) and their care recipients.

The participants of this randomized clinical trial will be 60 self-reported AACA aged 40 to 65 years old who identify as Chinese or Korean; are family caregivers of People Living with Alzheimer Disease (PLAD); can read and write English, Mandarin Chinese or Korean; who reside in the U.S.; and have access to the Internet through computers or mobile devices. Participants will be recruited through both online and offline communities/groups for Asian Americans. The recruitment settings are identified through both Internet searches and recommendations by research team members. When potential participants of Phase 2 visit the project Web site (after receiving/reviewing a study announcement), they will be asked to review the informed consent. When participants click I agree to participate, they will have given their consent. No identity information, including IP addresses, will be attached to any of the individual or group data. Therefore, research participants will not be identifiable directly or through the identifying information linked to subjects. Only research staff will have access to the data. Phase 2 study consists of two groups of research participants: (a) a control group who does not use the technology-based program, but uses the information on Alzheimer's Disease and caregiving by the Alzheimer's Association website; (b) an intervention group who uses the technology-based program and the information by the Alzheimer's Association website. Both groups will participate in the study for 3 months. During the research process, both groups are asked to fill out the Internet survey questionnaire (through the REDCap system) at three times (pre-test, post-1 moth, and post 3-months); if requested, paper-and-pencil questionnaires will be provided/used, or research staff will assist in administering the Internet surveys over the phone. Data will be collected only through the Internet survey, and each survey takes about 20 to 30 minutes to complete. Only for the intervention group, weekly group and individual coaching/support (max 1hr/week) by culturally matched bilingual interventionists will be provided through the online forum and chatting functions on the project website, phone calls, or text messages through ethnic-specific communication apps, and the participants are asked to use the educational modules, virtual reality app, and online resources that are available on the project website. The data collected through the Internet surveys will be stored on the HIPAA compliant clouds maintained by The University of Texas at Austin. All documentation related to the study will be also stored on the HIPAA compliant clouds maintained by The University of Texas at Austin.
Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.
In addition to the standard wound care procedure, the Music Therapy group (intervention group 2) will be hearing their preferred audio, chosen by patient to be relaxing and to offer distraction, through headphones during wound care. This group wears the headphone with music 10 minutes before the start of the wound care, until 1 minute after the wound care has ended.
The invention relates to a construction method of a novel DNA reticular nano medicine carrying molecule aiming at tumor therapy. A DNA tetrahedron (TDN) and nano gold are compounded to form a nano reticular structure. The method comprises the following steps: preparation of a DNA TDN structure; preparation of gold nano particles with the particle size of 4nm; and combination of the DNA TDN and the gold nano particles. The DNA TDN in the invention is accurate and controllable in size and switch and very stable in property. According to the invention, DNA and nano gold particles are creatively used to connect the DNA TDN so as to form a large reticular structure. The medicine carrying molecule mainly takes DNA as a raw material so as to be harmless to human bodies, so that the medicine carrying molecule is hopeful to be widely applied to the fields of research and therapy of tumors.
There was no evidence of carcinogenicity when mice and rats received ivabradine up to 104 weeks by dietary administration. High doses in these studies were associated with mean ivabradine exposures of at least 37 times higher than the human exposure (AUC 0-24hr) at the MRHD. 

Ivabradine tested negative in the following assays: bacterial reverse mutation (Ames) assay, in vivobone marrow micronucleus assay in both mouse and rat, in vivochromosomal aberration assay in rats, and in vivounscheduled DNA synthesis assay in rats. Results of the in vitrochromosomal aberration assay were equivocal at concentrations approximately 1,500 times the human C maxat the MRHD. Ivabradine tested positive in the mouse lymphoma assays and in vitrounscheduled DNA synthesis assay in rat hepatocytes at concentrations greater than 1,500 times the human C maxat the MRHD. 

Reproduction toxicity studies in animals demonstrated that ivabradine did not affect fertility in male or female rats at exposures 46 to 133 times the human exposure (AUC 0-24hr) at the MRHD.
The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
In this arm, one-half of the study subjects will not receive BMX-001 but will undergo all components of standard therapy (radiation therapy plus temozolomide \[TMZ\]). A total of 80 subjects will be in this study arm.
Individuals in this group will perform mat pilates exercises under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 exercise sessions. During the exercise sessions, individuals will undergo a 50-minute mat pilates exercise program. In addition to the mat pilates exercise group, on the days when he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
A method of producing animal's virus and bacterial vaccine by using vegetable oil adjuvant. It comprises the following steps,(1)make antigen agents, gain the antigens by copying the sprout bacterial strain with the sensitive cells and culture medium, and then deactivating them; produce the antigen agents by the antigens;(2)make vegetable oil adjuvant; (3)mixing, mix the antigen agents and the vegetable oil adjuvant proportional, homogeneous, and finish the vaccine. Wherein, the antigen agents are mixed with antigens and disinfection tuwen-80; the vegetable oil adjuvant is mixed with vegetable oil and span-80. The invention adopts new adjuvant to make the vaccine. When it is applied, it won't affect the immune efficiency of the vaccine, can drop the vaccine's untoward reaction, and is beneficial to produce safety meat foot. Compared to the current techniques, it has evident advantages. The invention is suit to various applications of animal virus and bacterial vaccine.
The intervention was a 16-minute educational video created by the study investigators which provided information about Down syndrome, diagnostic tests and screening tests. The screening tests covered in the video included the triple test, the combined first trimester screen and non-invasive prenatal screening. Information about how and when each of the tests were performed, their detection rates and possible results and their interpretations were covered in the video. The video was viewed by several healthcare providers and experts in the field of prenatal screening before the commencement of this study to ensure that the content was appropriate and adequate. The intervention was viewed by subjects on a portable tablet in a quiet room in the antenatal clinic. Subjects were then invited to ask their doctor any questions that they may have had about the video during the clinic consult which followed.
BACKGROUND: Substantial studies reveal that tertiary lymphoid structure (TLS) correlate with prognosis and immunotherapy response in various types of cancers. However, the predictive value of TLS, the specific immune cell subtype within TLS and their anti-tumor mechanisms remain unclear.
METHODS: Based on 23 TLS-related genes (TLSRGs), we utilized bioinformatics methods to construct a scoring system, named TLSscore. By integrating RNA and single-cell sequencing data, we assessed the utility of TLSscore in head and neck squamous cell carcinoma (HNSCC). Flow cytometric sorting was used to isolate specific T cells subtypes, in vivo and in vitro experiments were conducted to demonstrate its anti-tumor effects.
RESULTS: The TLSscore model was constructed and specific TLSscore-genes were found to consistently align with the spatial location of TLS. TLSscore has proven to be a robust predictive model for predicting survival prognosis, immune cell infiltration, somatic mutation and immunotherapy response. Notably, a specific PD1+CXCL13+CD8+T cell subtype was identified within TLS. Both in vivo and in vitro experiments demonstrated that PD1+CXCL13+CD8+T cell might represent a functional cell subtype exerting anti-tumor effects during the process of immune surveillance.
CONCLUSIONS: Our study presents a predictive model for TLS, which can evaluate its presence and predicts survival prognosis and immunotherapy response in HNSSC patients. Additionally, we identify a specific subtype of T cells that might elucidate the mechanism of TLS function in anti-tumor activities. This T cell subtype holds the potential to be a prognostic marker and a target for adoptive cell therapy (ACT) in the future.
PURPOSE: This study aimed to determine factors associated with multimodal care practices for cancer cachexia among registered dietitians (RDs) working in cancer care.
METHODS: A secondary analysis was performed using RDs' data. Data on knowledge, skills, and confidence in multimodal care were obtained. Nine items regarding multimodal care practices were evaluated. Subjects were divided into two groups based on their answers associated with the nine items. Comparisons were obtained using the Mann-Whitney U test or chi-squared test. Multiple regression analysis was performed to identify the critical factors involved in practicing multimodal care by determining the variables with significant differences between the two groups.
RESULTS: Two hundred thirty-two RDs were included in this study. Significant differences were observed in their primary area of practice (p = 0.023), the number of clinical guidelines used (p < 0.001), the number of items used in cancer cachexia assessment (p = 0.002), the number of symptoms used in cancer cachexia assessment (p = 0.039), training for cancer cachexia (p < 0.001), knowledge of cancer cachexia (p < 0.001), and confidence in cancer cachexia management (p < 0.001). The number of symptoms used in cancer cachexia assessment (B = 0.42, p = 0.019), knowledge of cancer cachexia (B = 6.60, p < 0.001), and confidence in cancer cachexia management (B = 4.31, p = 0.010) were identified as critical factors according to the multiple regression analysis.
CONCLUSION: The RDs' knowledge and confidence in cancer cachexia management were associated with their multimodal care practices.
For: Dose escalation phase/Phase II Expansion Phase. Cohorts of 3-6 patients were to be enrolled sequentially until an MTD or a recommended Phase II dose were defined. All patients were to receive the combination treatment. Sequential cohorts may receive different doses of the combination. In the Phase II expansion, all patients were to receive the same combination treatment.